top of page
Browse by category
Search
Early data shows Revita has potential to prevent weight regain after GLP-1 discontinuation
Fractyl Health has announced positive early data from the open-label REVEAL-1 cohort of its ongoing REMAIN-1 pivotal study. The results...
German Real-World Registry shows meaningful and sustained weight loss for at least one year after a single Revita endoscopic procedure
Fractyl Health has announced new weight maintenance and blood sugar clinical results from the Company’s German Real-World Registry for...
FDA grants Breakthrough Device Designation for Fractyl’s Revita in weight maintenance for people with obesity who discontinue GLP-1s
The FDA has granted Breakthrough Device Designation (BDD) for Fractyl Health’s Revita System for use in the maintenance of weight loss...
Revita German Real-World Registry: First 14 participants continue to demonstrate sustained improvements in blood glucose and weight
Six-month follow-up data from Fractyl Health’s Revita German Real-World Registry has reported that he first 14 consented registry...
FDA Approves IDE study assessing Revita for weight maintenance after discontinuation of GLP-1
The FDA has approved a pivotal Investigational Device Exemption (IDE) to study the efficacy of Fractyl Health’s Revita system for...
Revita results in weight loss and sustained weight maintenance without weight regain at one year
The latest weight maintenance data from a pooled analysis of patients enrolled in Revita (Fractyl Health) clinical studies across the EU...
Fractyl’s Revita DMR System commercially available in Germany
Fractyl Health has announced the commercial availability of its Revita DMR System in Germany, an endoscopic procedural therapy that is...
Fractyl Health reports latest Revita DMR outcomes for T2DM
New data from Fractyl Health’s Revita-1 and Revita-2 studies presented at Digestive Disease Week 2022 builds on this earlier evidence to...
Two-year Revita DMR outcomes show durability of procedure in diabetics
Two-year durability data from the REVITA-1 clinical study, conducted at centres in Europe and South America, revealed that HbA1c was...
Fractyl gains US$100 million financing to expand clinical development programs for T2DM
Fractyl Health (formerly Fractyl Laboratories) has closed a US$100 million Series F financing to support multiple late-stage clinical...
Browse by tag
bottom of page